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Cleavagevirus type 1 (HIV-1) entry into host cells is mediated by the trimeric envelope
glycoprotein complex (Env). Accordingly, the Env proteins are the targets for neutralizing antibodies (NAbs)
and are the focus of vaccines intended to induce NAbs. Because the Env complex is labile, soluble
recombinant Env (gp140) trimers require engineering to stabilize them sufﬁciently for use as immunogens.
Trimeric forms of gp140 trimers can be created that are either cleavage-competent or cleavage-defective at
the junction between the gp120 and gp41 subunits. As functional trimers are cleaved at this site, the question
arises as to whether cleavage affects the antigenic structure of the Env complex in a way that is relevant to
vaccine design. Here, we present a comparative analysis of the antigenicity proﬁles of cleaved and uncleaved
gp140 trimers derived from the KNH1144 (subtype A) virus that are otherwise closely sequence-matched.
While cleavage did not affect the exposure of NAb epitopes on the gp140 trimers, non-neutralizing antibodies
to gp41 epitopes bound much more strongly to uncleaved trimers. Hence cleavage does alter the structure of
the HIV-1 Env complex.
© 2008 Elsevier Inc. All rights reserved.IntroductionVarious different forms of human immunodeﬁciency virus type 1
(HIV-1) Env glycoproteins have been expressed as recombinant
proteins for vaccine and/or structural studies over the past 25 years.
The Env conﬁgurations most commonly studied in recent years have
been oligomeric gp140s that contain the gp120 surface glycoprotein
and the ectodomain of the gp41 transmembrane glycoprotein; the
constructs are truncated immediately before the membrane-spanning
domain of gp41, to allow expression of the gp140s as soluble proteins.
The secreted gp140s are heterogeneous in that multiple molecular
forms can be present, including gp120–gp41 monomers, dimers,
trimers, tetramers and higher molecular weight aggregates, the
proportions of which vary with the HIV-1 genotype, the nature of
the mutations introduced to create the gp140 and probably even the
cell type used for protein expression (Binley et al., 2000; Jeffs et al.,
2004; Schulke et al., 2002). In general, the goal of expressing a gp140
protein is to make trimers that mimic, as closely as possible, the native
conﬁguration of Env as it exists on infectious viruses. Hence a trimer-
enriched fraction needs to be puriﬁed from the mixture of Env forms
that are normally present in gp140 preparations.re).
, 45 Sidney Street, Cambridge,
l rights reserved.The native Env trimer is unstable, because the inter-subunit
interactions (gp120–gp41 and gp41–gp41) are non-covalent and
weak, a situation that reﬂects the need for Env to undergo multiple,
complex conformational changes during fusion of HIV-1 with its
target cells. This instability complicates gp140 expression; the desired
trimers tend to dissociate, or in some cases aggregate, rapidly into
non-native Env forms (Jeffs et al., 2004). The latter interfere with
structural studies and they are unlikely to be immunogens that are
capable of inducing broadly neutralizing antibodies at high titers.
Hence strategies must be adopted to increase trimer stability. The
most common way to do this has been to mutate the cleavage site
between gp120 and gp41 to prevent processing by furin-like cellular
endoproteases. This device stabilizes the gp120 and gp41 interaction,
which remains covalent. The introduction of heterologous trimeriza-
tion domains at the gp140 C-terminus can help stabilize uncleaved
gp140s in a trimeric conﬁguration (Yang et al., 2002; Yang et al., 2000).
An alternative way to maintain gp120–gp41 association is the
introduction of an intermolecular disulﬁde bond (SOS) between the
two subunits (Binley et al., 2000); together with point substitutions
within gp41 (Sanders et al., 2002), this strategy allows the expression
and puriﬁcation of fairly stable, fully cleaved gp140 trimers.
There has been an increasing appreciation that cleaved and
uncleaved forms of gp140 trimer are antigenically different. In other
words, whether an Env trimer is cleaved or not appears to affect the
antibody epitopes it expresses. However, the studies fromwhich these
conclusions are drawn are complicated by the presence of non-trimer
forms of Env, either on the cell surface or present within
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clear what Env forms are being bound by test MAbs. Moreover,
structural studies show that cleavage has only a minimal effect on the
subunit topology of other RNA virus fusion glycoproteins (e.g.,
inﬂuenza HA (Stevens et al., 2004), Sindbis virus (Smit et al., 2001)).
In the absence of a crystal structure of HIV-1 Env trimers, the precise
effects of cleavage on gp120–gp41 structure are unknown. However,
to gain more understanding of what cleavage might do, we have now
studied epitope exposure on puriﬁed, cleaved and uncleaved forms of
gp140 from the KNH1144 strain of HIV-1 that differ only at the
cleavage site between gp120 and gp41. We conclude that cleavage
does indeed affect the topology of gp140 trimers, in that various non-
neutralizing MAbs bind to the gp41 moieties of uncleaved but not
cleaved trimers. Structural studies may eventually enable these
observations to be understood at a molecular level.
Results
Expression and stability of cleaved and uncleaved gp140s from KNH1144
SOSIP gp140 proteins from the KNH1144 subtype A strain lack the
consensus epitopes for NAbs 2G12, 2F5 and 4E10. We therefore
recreated these epitopes to make cleaved (KNH1144 SOSIP.R6 G-
MPER) and uncleaved (KNH1144 SOSIP.IEGR G-MPER) gp140 variants
that were otherwise identical in sequence (see Fig. 1A and Methods).
MAbs 2G12, 2F5 and 4E10 all bound strongly to the cleaved gp140 (Fig.Fig. 1. Expression and analysis of soluble, cleaved (SOSIP.R6 G-MPER) and uncleaved (SOSIP.I
mutations made in the KNH1144 primary sequence to generate a stabilized soluble trimeric g
(S295N), and to improve 2F5 and 4E10 binding (MPER-A662E, G664D, N668S and T671N). (B)
G-MPER gp140 sequence by site-directedmutagenesis, to create the SOSIP.R6 G-MPER varian
Unpuriﬁed cell culture supernatants containing the same cleaved or uncleaved gp140s were
C1 region of gp120. The migration positions of relevant molecular weight standards are mark
The same cleaved (lanes 1 and 2) and uncleaved (lanes 3 and 4) gp140s were analyzed by SD
Western blotting. The SOSIP.R6 G-MPER gp140 is fully cleaved and hence dissociates to gp12
(lane 4).1B) and also to their uncleaved counterpart (data not shown). These
two epitope-modiﬁed gp140 proteins were used in all the MAb-
binding studies described below.
Both the cleaved and uncleaved KNH1144 gp140s were predomi-
nantly trimeric after expression in HEK293T cells, as assessed on a
non-denaturing, gradient polyacrylamide gel (Fig. 1C). Under denatur-
ing conditions, the SOSIP.R6 G-MPER gp140 was N95% cleaved, in that
it dissociated to gp120 in the presence of DTT (Fig. 1D; the gp41 band
is not shown). In contrast, the SOSIP.IEGR G-MPER gp140 was, as
intended, completely uncleaved and thereby remained as a gp140
when DTT was present (Fig. 1D). Hence the two constructs are suitable
templates for further studies of the effect of cleavage on trimer
stability and conﬁguration.
Puriﬁcation of cleaved and uncleaved gp140 trimers
The cleaved and uncleaved gp140s were puriﬁed on an oligosac-
charide-speciﬁc GNA (Galanthus nivalis agglutinin)-lectin afﬁnity
column. The eluted proteins were then fractionated, based on their
relative hydrodynamic size, using gel ﬁltration chromatography (Fig.
2A). The different forms of both cleaved and uncleaved gp140s
(monomer, dimer and trimer) were well resolved into distinct peaks
on a Superose6 column. The uncleaved trimers migrated very slightly,
but consistently, less rapidly than their cleaved counterparts but,
overall, the two gp140 preparations had almost identical gel-ﬁltration
chromatography proﬁles.EGR G-MPER) gp140s from HIV-1 KNH1144. (A) Schematic representation of the various
p140 (SOS, IP), to promote (R6) or disrupt (IEGR) cleavage, to introduce the 2G12 epitope
The epitopes for MAbs 2G12, 2F5 and 4E10 were introduced into the KNH1144 SOSIP.R6
t. Binding of these MAbs to the two gp140s was determined by immunoprecipitation. (C)
analyzed by BN-PAGE andWestern blotting with MAb CA13 (ARP3119) that binds to the
ed on the left of the gel. Both the cleaved and uncleaved gp140s migrate as trimers. (D)
S-PAGE in the presence or absence of the reducing agent, DTT, as indicated, followed by
0 in the presence of DTT (lane 2), whereas the SOSIP.IEGR G-MPER protein is not cleaved
Fig. 2. Gel ﬁltration analysis of cleaved and uncleaved gp140s. (A) The SOSIP.R6 G-MPER (cleaved) and SOSIP.IEGR G-MPER (uncleaved) gp140s were puriﬁed by lectin-afﬁnity
chromatography and then analyzed by size-exclusion chromatography. The separation proﬁle of the two preparations over time (minutes) is shown. The solid arrow indicates the
high-molecular aggregate peak, whereas the three dotted arrows show the trimer, dimer andmonomer peaks. The precise timings (inminutes) of the three gp140 protomer peaks are
listed. (B, C) The gel-ﬁltration chromatography fractions (numbered above the lanes) were analyzed using BN-PAGE and Western blotting. The migration positions of relevant
molecular weight standards are marked on the left.
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column again showed that the cleaved and uncleaved gp140s were
very similar in their migration proﬁles (Figs. 2B and C). However,
higher molecular weight, disulphide-linked aggregates were present
only in the cleaved gp140 preparation (Fig. 2A). These aggregates form
a small shoulder just before the trimer peak (denoted by a solid arrow
in Fig. 2A). Since the purpose of these experiments was to compare
cleaved and uncleaved trimers, we did not further analyze the dimeric,
monomeric or other forms of gp140 that elute from the gel ﬁltration
column in and after fraction 31; we have reported elsewhere on the
presence of such Env forms in KNH1144 gp140 preparations (Dey et al.,
2007). The peak corresponding to the gp140 trimer fraction was
collected from the gel ﬁltration column and concentrated to the
desired volume. Subsequent references to ‘puriﬁed trimers’ refer to
this gp140 fraction, which we analyzed by ultracentrifugation and
other procedures as outlined below.
Ultracentrifugation analysis
Sedimentation equilibrium measurements were carried out to
determine the oligomeric state of the puriﬁed, cleaved and uncleaved
gp140s. The cleaved gp140 sedimented as a homogenous trimer; itsapparentmolecular mass is ∼460 kDa in the concentration range of 0.1
to 0.4 mg/ml (Fig. 3A). The uncleaved gp140 is also trimeric, with an
apparent molecular mass of ∼435 kDa (Fig. 3B). There was no
systematic dependence of apparent molecular mass on protein
concentration over a 4-fold range of protein concentration studied.
Nonetheless, analysis of residual differences from the trimeric model
reveals a systematic error, suggesting that the uncleaved gp140 is
prone to aggregation.
Stability of cleaved and uncleaved gp140 trimers
We assessed the stabilities of the puriﬁed, cleaved and uncleaved
gp140 trimers in the presence of different detergents, to gain an initial
understanding of their properties. Both forms of trimer dissociated
completely into monomeric gp140 subunits when incubated with the
ionic detergent SDS for 1 h at room temperature (Figs. 4A and B; lane
2). In the presence of non-ionic detergents (NP-40, Tween-20, Triton
X-100), the uncleaved gp140 trimers were highly stable (Fig. 4B; lanes
3, 4, and 5), whereas the cleaved trimers partially dissociated under
the same conditions. Thus, NP-40 treatment of the cleaved trimers
caused gp140 dimers to appear (Fig. 4A; lane 3), while exposure to
Tween-20 and Triton X-100 yielded both gp140 dimers and
Fig. 3. Sedimentation equilibrium analysis of cleaved and uncleaved gp140s. (A)
Sedimentation equilibrium data of SOSIP.R6 G-MPER gp140 at 0.2mg/ml in PBS (pH 7.0).
Data are plotted as ln(absorbance) versus the square of the radius from the axis of
rotation. The slope of the data is proportional to the molecular mass of the protein
oligomer. SOSIP.R6 G-MPER gp140 is a discrete trimer under these conditions. (B)
Sedimentation equilibrium data of SOSIP.IEGR G-MPER gp140 at 0.4 mg/ml in PBS (pH
7.0). The slope of the plotted data indicates that the SOSIP.IEGR G-MPER gp140 is a
trimeric species.
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destabilizes the gp140 trimer.
The gp41 subunits are antigenically different in cleaved and uncleaved
gp140s
The binding of various neutralizing and non-neutralizing MAbs to
the puriﬁed, cleaved and uncleaved KNH1144 (G-MPER modiﬁed)
gp140 trimers was analyzed by immunoprecipitation in the absence of
detergent. There was no detectable difference in how CD4-IgG2 or any
of the anti-gp120MAbs (2G12, b12, F425–B4e8, A32,15e) reactedwith
the cleaved versus uncleaved trimers (Fig. 5A). CD4-induced con-Fig. 4.Detergent stability of cleaved and uncleaved gp140 trimers. Gel ﬁltration-puriﬁed (A) K
were incubated with 0.1% concentrations of the indicated ionic (SDS) or non-ionic (NP-40, Tw
blotting.formational changes that exposed the 17b epitope also occurred to a
similar extent with both forms of trimer (Fig. 5B). Hence cleavage does
not appear to have a major effect on the topology of the gp120 subunit
of trimers. The 2F5 and 4E10 NAbs to the gp41 MPER epitopes also
reacted similarly with the cleaved and uncleaved trimers (Fig. 5C).
However, whereas the non-neutralizing MAbs D50, 2.2B, 126-7 (all to
Cluster II epitopes), F240 and 7B2 (both to Cluster I epitopes) all bound
strongly to the uncleaved trimers, they did so only weakly or not at all
to the cleaved trimers (Fig. 5C). To assess whether the limited
reactivity of the cleaved gp140s with the non-neutralizing anti-gp41
MAbs was simply due to the absence of the relevant epitopes, we
repeated the immunoprecipitation reaction under denaturing condi-
tions; i.e., in the presence of 0.01% SDS. Under these conditions, all the
MAbs bound strongly (Fig. 5D), conﬁrming that their epitopes are
present but are normally occluded within the cleaved gp140 trimer.
Discussion
Does cleavage matter? We considered it something worth looking
into, from the perspective of HIV-1 vaccine development. Our overall
conclusion is that cleavage does affect the conformation of the gp41
component of trimeric gp140 proteins, as judged by the binding of
several non-neutralizing anti-gp41MAbs to uncleaved but not cleaved
gp140s. The addition of SDS reveals these epitopes on the cleaved
trimers, showing that they are present on the protein but are normally
occluded. As both Cluster I (residues 579 to 613) and Cluster II
(residues 644 to 667) epitopes are affected, severing the link between
gp120 and gp41must signiﬁcantly reduce the exposure of a signiﬁcant
fraction of the total gp41 surface. The likeliest explanation is that the
non-neutralizing gp41 MAb epitopes are shielded by other compo-
nents of the trimer, either by the gp120 subunits or by intermolecular
interactions between the gp41 subunits. Another possibility is that the
cleaved trimers might be ﬁxed in a conformation in which non-
neutralizing Cluster I and Cluster II epitopes are occluded, but other
gp41 regions are exposed for which no antibody probes exist.
Structures of cleaved and uncleaved trimers would be needed to
discriminate between these and other possibilities.
That Cluster I and Cluster II MAbs do not neutralize infectious
viruses implies that their epitopes are also occluded on functional,
native, cleaved trimers, a view supported by recent electron micro-
graphs of the spike structures (Liu et al., 2008). Moreover, the binding
of soluble CD4 to Env on the surface of HIV-1 LAI-infected cells
increases the exposure of several non-neutralizing MAb epitopes
located within gp41 residues 521–663, but does not affect NAb 2F5
binding to its MPER epitope at residues 662–667 (Sattentau et al.,
1995). The strong reactivity of the non-neutralizing gp41 MAbs with
the uncleaved trimers therefore implies that the gp41 components of
these proteins are in a non-native conﬁguration in which a major
fraction of the gp41 surface is abnormally exposed. As NAbs 2F5 and
4E10 bind with comparable efﬁciencies to the cleaved and uncleaved
gp140s, the structural effects of cleavage on gp140 conformation do
not extend to the extreme C-terminal region of gp41. Overall, cleavedNH1144 cleaved SOSIP.R6 G-MPER and (B) uncleaved SOSIP.IEGR G-MPER gp140 trimers
een20, Triton×100) detergents for 1 h at 25 °C, before analysis by BN-PAGE andWestern
Fig. 5. Reactivity of anti-gp120 and anti-gp41 MAbs with cleaved and uncleaved gp140 trimers. Gel ﬁltration-puriﬁed cleaved (SOSIP.R6 G-MPER) or uncleaved (SOSIP.IEGR G-MPER)
gp140 trimers were immunoprecipitated with various MAbs, and then analyzed by SDS-PAGE and Western blotting. (A) Anti-gp120 MAbs and the CD4-IgG2 protein were tested. (B)
MAb 17b to a CD4-induced epitope was tested in the presence or absence of sCD4. (C) Anti-gp41 MAbs were tested. (D) Several of the anti-gp41 MAbs were re-tested for binding to
cleaved gp140 trimers, but now in the presence of SDS.
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they appear to be better mimics of the native Env spike.
Previous studies from various groups, including our own, have also
suggested that cleaved and uncleaved forms of HIV-1 Env differ in
their antigenic structure, particularly in respect of the gp41 compo-
nents. However, all the earlier reports on soluble gp140s compared
proteins with sequence differences that were not limited to the
cleavage site, thereby complicating the nature of any conclusions
(Binley et al., 2000; Binley et al., 2002; Sanders et al., 2002; Stamatatos
et al., 2000; Yang et al., 2000, 2002). In the present experiments the
cleaved and uncleaved KNH1144 SOSIP Env proteins have identical
sequences outside the cleavage site, which eliminates other possible
variables. MAb reactivity assays using Env proteins expressed on the
surface of transfected cells have also shown signiﬁcant differences
between cleaved and uncleaved proteins, including differences in how
neutralizing and non-neutralizing MAbs bind to the gp120 subunits
(Pancera and Wyatt, 2005). Thus, only gp120-directed neutralizing
MAbs (and soluble CD4) bound efﬁciently to properly cleaved
glycoproteins, whereas both non-neutralizing and neutralizing MAbs
bound the uncleaved Env complex. This again implies that signiﬁcant
changes in Env spike structure arise when the gp160 precursor is
cleaved (Pancera and Wyatt, 2005). We did not see differences in
gp120 MAb reactivity with the soluble gp140s; various neutralizing
and non-neutralizing anti-gp120 MAbs bound comparably to both
forms. An explanation of the difference between our results and those
seen with the full-length Env glycoproteins is that, in the latter, the
transmembrane and cytoplasmic domains inﬂuence the conformation
of the gp120 subunits, and in a cleavage-dependent manner.
Modulations of Env conformation by these domains are not, of course,
relevant to soluble gp140s. An alternative explanation is that the
intermolecular SOS bond and the I559P substitution that are common
to both the uncleaved and cleaved proteins also act to minimize any
inﬂuences of cleavage on the gp120 component of soluble gp140s.
The marked conformational difference between the cleaved and
uncleaved forms of HIV-1 gp140s stands in contrast with what has
been learned from studies of other viral fusion proteins, notably
inﬂuenza HA (Stevens et al., 2004), Ebola virus glycoprotein (Wool-
Lewis and Bates, 1999), mouse hepatitis virus (MHV) A59 glycoprotein
(Bos et al., 1997; Hingley et al., 1998) and Sindbis virus E2 glycoprotein
(Russell et al., 1989). Of particular note is that the crystal structure ofthe uncleaved form of the human H1 hemagglutinin (HA) from
Inﬂuenza virus showed that the cleavage event only minimally alters
the local structure of the transmembrane glycoprotein and its
antigenic sites (Stevens et al., 2004). In addition, in vitro and in vivo
studies on several viruses have shown that Env glycoprotein cleavage
is not always necessary for virus maturation/assembly or infectivity,
implying that cleavage has little effect on function (Bos et al., 1997;
Hingley et al., 1998; Russell et al., 1989; Watanabe et al., 1995).
However, these conclusions are often derived from one-step infection
assays; it is possible that additional selection pressures are exerted in
multiple replication rounds, and/or in vivo, that result in the retention
of the highly conserved cleavage motif. Semliki Forest Virus (SFV) Env
may, however, more closely resemble HIV-1 gp160. Thus, cleavage of
the SFV Env precursor causes a dramatic, but localized, rearrangement
of the trimeric spike on the surface of the virion, an event that does not
happenwith amutant (uncleaved) formvariant (Ferlenghi et al.,1998).
Structural studies on cleaved and uncleaved trimers may even-
tually enable the present observations to be understood at amolecular
level. Whether the differences between these different types of trimer
truly matter for the design of HIV-1 vaccines is hard to judge, because
of the difﬁculty in predicting how antigenic structural variation affects
the generation of immune responses. Both forms of trimer express the
epitopes for the kinds of NAbs that a vaccine should induce, and to
comparable extents. However, there has been speculation that the
development of immune responses to non-neutralization epitopes is a
hindrance to the generation of NAbs (Binley et al., 2004; Burton et al.,
2005; Eggink et al., 2007; Moore et al., 2006; Pantophlet et al., 2003;
Selvarajah et al., 2005). If this truly is the case, then using cleaved
proteins would seem the better approach, particularly if other non-
neutralization epitopes can be eliminated by additional engineering.
In the end, only comparative immunization studies would resolve this
point and determine whether cleavage is important.
Materials and methods
Plasmids for expression of cleaved and uncleaved gp140s from HIV-1
KNH1144
We have previously described the stable expression of gp140
trimers from the subtype A strain KNH1144, using pPPI4 eukaryotic
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nated KNH1144 SOSIP.R6) was generated by inserting a disulphide
bond (SOS) between gp120 and gp41 (Binley et al., 2000), making a
single point substitution in gp41 (I559P) (Sanders et al., 2002), and
introducing a cleavage-enhancing hexa-arginine (R6) motif in place of
the natural REKR sequence at the cleavage site between gp120 and
gp41 (Binley et al., 2002). As the epitopes for MAbs 2G12, 2F5 and
4E10 are either absent or not optimal in the primary sequence of
KNH1144, they were created via mutagenesis of the KNH1144 SOSIP.
R6 sequence. For 2G12, this was achieved via a S295N change in
gp120; for 2F5 and 4E10, we altered the gp41 sequence ALGK-
WANLWT to ELDKWASLWN. The speciﬁc amino acid substitutions
were made using the QuikChange® II XL site-directed mutagenesis kit
(Stratagene Inc., La Jolla, California) and the appropriate primers. The
introduced mutations were veriﬁed by sequencing. The 2G12, 2F5 and
4E10 epitope-modiﬁed protein was designated KNH1144 SOSIP.R6 G-
MPER, where G refers to the glycan-modiﬁcation and MPER refers to
the substitutions in the membrane proximal external region. The
uncleaved gp140 (called KNH1144 SOSIP.IEGR G-MPER) contains the
same SOS, I559P and G-MPER substitutions but the REKR sequence
was mutated to IEGR to prevent cleavage (Schulke et al., 2002). Hence
other than at the cleavage site, the cleaved and uncleaved KNH1144
Env proteins have identical sequences. The furin gene was expressed
from plasmid pcDNA3.1furin (Binley et al., 2000).
MAbs and CD4-based proteins
The following anti-gp120 monoclonal antibodies (MAbs) were
used: IgG1b12 (against the CD4 binding site (Burton et al., 1991));
2G12 (against a mannose-dependent epitope (Scanlan et al., 2002;
Trkola et al., 1996)); 17b (against a CD4-inducible epitope (Thali et al.,
1993)); F425–B4e8 (against the V3 loop (Cavacini et al., 2003)). All the
above antibodies were obtained from the IAVI NAC repository. Soluble
CD4 (sCD4) and the CD4-based molecule CD4-IgG2 were obtained
from Progenics Pharmaceuticals (Allaway et al., 1995).
The anti-gp41 MAbs used were: 2F5 (against an epitope centered
on the sequence LELDKWANL (Zwick et al., 2005)); 4E10 (against an
epitope centered on the sequence NWFDIS (Zwick et al., 2005); D50
(642–665) (Earl et al., 1997); 126-7 (Zhou et al., 2007); F240 (Cavacini
et al., 1998; Duval, Posner, and Cavacini, 2008); 2.2B, 7B2. MAbs F240
(aa 598 to 604) (Duval, Posner, and Cavacini, 2008) and 7B2 (Haynes et
al., 2005) were to gp41 Cluster I, MAbs D50, 2.2B (Haynes et al., 2005)
and 126-7 were to gp41 Cluster II. All the anti-gp41 MAbs were
obtained via NIH the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH, except for 2.2B and 7B2 that were kindly
provided by James Robinson. MAb CA13 (ARP3119), which binds to C1
region of gp120, was obtained from Ms C. Arnold via the EU
Programme EVA Centralized Facility for AIDS Reagents, NIBSC, UK
(AVIP Contract Number LSHP-CT-2004-503487). This MAb was used
for all Western blotting assays described in this study.
Expression and puriﬁcation of cleaved and uncleaved gp140
glycoproteins
Cleaved and uncleaved trimers were transiently expressed in
adherent HEK293T cells by transfection with gp140- and furin-
expressing plasmids, using linear 25K Polyethylenimine (PEI) (Poly-
sciences Inc., Warrington, PA), as described previously (Beddows et al.,
2007; Binley et al., 2000; Dey et al., 2007). Culture supernatants that
contained Env glycoproteins were concentrated by N20-fold and then
subjected to lectin-afﬁnity chromatography. The column eluate was
then size-fractionated using an analytical Superose™ 6 column (GE
Amersham Pharmacia, Piscataway, NJ) equilibrated with phosphate-
buffered saline (PBS; 100mMNaCl, 50mM sodiumphosphate, pH 7.0).
The column was calibrated with protein standards of known
molecular weights (HMW Gel Filtration Calibration Kit; AmershamPharmacia, Piscataway, NJ). Fractions (200 μl) were collected and
analyzed using Blue-native polyacrylamide electrophoresis (BN-PAGE)
and SDS-PAGE. Quantiﬁcation of proteins was carried out using the
BCA quantiﬁcation kit (Pierce) with known BSA standards, as
described previously (Dey et al., 2007; Schulke et al., 2002).
SDS-PAGE, BN-PAGE, immunoprecipitation and Western blot analyses
SDS-PAGE analyses were performed as described elsewhere
(Binley et al., 2000). Reduced and non-reduced samples were
prepared in Laemmli sample buffer (62.5 mM Tris–HCl, pH 6.8, 2%
SDS, 25% glycerol, 0.01% DTT) and boiled for 5 min in the presence or
absence of 50 mM dithiothreitol (DTT), respectively. BN-PAGE was
carried out as described previously (Schulke et al., 2002). Gel
electrophoresis was performed for 2 h at 150 V (∼0.07 A) using
50 mM MOPS, 50 mM Tris, pH 7.7, 0.002% Coomassie blue as the
cathode buffer, and 50 mM MOPS, 50 mM Tris, pH 7.7 as the anode
buffer. When puriﬁed proteins were analyzed, the gel was destained
with several changes of 50 mM MOPS, 50 mM Tris (pH 7.7) buffer,
subsequent to the electrophoresis step.
Immunoprecipitation was carried out by incubating known
concentrations of cleaved and uncleaved gp140s overnight at 4 °C
with CD4-IgG2 or variousMAbs (250 ng) in a buffer containing 50 mM
Tris–HCl (pH 7.0), 150 mM NaCl and 1 M EDTA. The gp140-MAb/CD4-
IgG2 complexes were then precipitated using ImmunoPure® immo-
bilized Protein G agarose beads (Pierce Biotechnology, Rockford, IL)
and analyzed by reducing SDS-PAGE.
The Western blot procedure has been described elsewhere
(Schulke et al., 2002). Following transfer, the polyvinylidene diﬂuoride
(PVDF) membrane was destained, then probed using anti-Env MAb
CA13 (ARP3119), followed by horseradish peroxidase-labeled anti-
mouse immunoglobulin G (IgG) (Kirkegaard and Perry Labs), at a ﬁnal
concentration of 0.2 μg/ml. The bound MAbs were detected using the
Western Blot Chemiluminescence Reagent Plus system (Perkin-Elmer
Life Sciences, Boston, MA). Protein mixtures containing Thyroglobulin
(669 kDa), Ferritin (440 kDa), Catalase (232 kDa), Lactate dehydro-
genase (140 kDa) and BSA (66 kDa) (Amersham Biosciences) were
used as standard markers for native gels; the MultiMark® multi-
colored standard set (Invitrogen) was used for denaturing gels.
Sedimentation equilibrium experiments
Analytical ultracentrifugation measurements were performed on a
Beckman XL-A Optima analytical ultracentrifuge with an An-60 Ti
rotor at 20 °C. Protein samples were dialyzed overnight into PBS buffer
(50 mM sodium phosphate, pH 7.0, 150 mM NaCl), loaded at initial
concentrations of 0.1, 0.2 and 0.4 mg/ml, and analyzed at rotor speeds
of 3500 and 5000 rpm. Data were acquired at two wavelengths per
rotor speed and were ﬁt using the program NONLIN to a single species
model of the natural logarithm of the absorbance versus radial
distance squared (Johnson et al., 1981). Solvent density and protein
partial speciﬁc volume parameters were calculated taking into
account the solvent and protein composition, respectively (Laue et
al., 1992).
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